← All trials
NCT04841096
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Aug 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- Apr 12, 2021
- Last posted
- Jun 10, 2021
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Laboratorios Silanes S.A. de C.V.Lead sponsor
- Centro de Investigación Médica Aguascalientes (Red OSMO)Overall official - principal investigator
- Centro de Investigación Médica Aguascalientes (Red OSMO)Overall official - principal investigator
- Oncológico Potosino (Red OSMO)Overall official - principal investigator
- Mérida Investigación ClínicaOverall official - principal investigator
- Mérida Investigación ClínicaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.